Vaxil’s primary platform enables integrated identification, isolation, and production OF ANTIGEN-SPECIFIC IMMUNOTHERAPIES
Vaxil’s VaxHit™ platform technology combines proprietary algorithms which enable in-silico identification of signal peptides domains and their subsequent use as immunotherapeutic products. The VaxHit™ platform is essentially a launchpad for novel and uniquely targeted immunotherapy products.
Vaxil is building a robust pipeline of immunotherapy products intended to target cancer antigens in an altogether novel and more specific manner. The below graphic is interactive, click on each product to learn more.
| 1 | PLATFORM |  |
VAXIL’S PRIMARY PLATFORM: Proprietary Identification, isolation, and production OF ANTIGEN-SPECIFIC IMMUNOTHERAPIES | |||
| Pre Clinical | Phase I | Phase II | Phase III | |||
|---|---|---|---|---|---|---|
| 2 | ANTIGEN SPECIFIC IMMUNOTHERAPIES |  |
First VaxHit™ Generated Immunotherapy MUC1 selected as pilot target in order to demonstrate VaxHit’s ability as a platform to generate immunotherapies capable of targeting otherwise “untouchable” renowned antigens. | Phase-I/II complete15 myeloma patients Published BJH 2014 Orphan Drug | ||
| Additional SP specific immune therapies in progress | Follow-on products targeting other high profile cancer antigens | |||||
| 3 | SIGNAL PEPTIDE SPECIFIC ANTIBODIES |  |
Novel antibodies therapeutic & diagnostic | First ever SP-specific antibodies & far more specific against targets | ||
 |
Novel antibodies therapeutic & diagnostic | First ever SP-specific antibodies & far more specific against targets | ||||
| 4 | ANTI-INFECTIVES |  |
Derived from SP domains of 5 known TB vaccines | VaxHit™ has also led to vaccines for pathogens Superior immunity observed in large #’s | ||
VAXIL IMMUNOTHERAPY Intellectual Property rights
Vaxil believes its immunotherapy platform to be an altogether novel and advantageous avenue for targeting cancer. The Company has made efforts to protect its robust intellectual property portfolio in order to cover its proprietary products. Most importantly, however, is the protection afforded to VaxHit as a platform with the potential to generate additional immunotherapies targeting a range of cancer antigens in the same advantageous manner. Vaxil currently holds 6 fully issued patents, with an additional 10 patents pending.Given Vaxil’s highly novel approach to immunotherapy, the Company believes its VaxHit™ platform possesses potential perhaps not yet understood or appreciated by the broader market. The Company is, therefore, utilizing the opportunity to amass a strong and broad intellectual property for ImMucin™ and even more so for VaxHit™ as an extensive platform with potential to generate additional immunotherapies targeting prevalent cancer antigens. Vaxil has already identified tens of possible immunotherapy product candidates utilizing its platform. Most importantly, VaxHit™ derived immunotherapy products (including ImMucin™) all contain the several critical advantages
Vaxil’s IP Portfolio is divided into Three Patent-Families Vaxil holds a total of 6 issued patents and 10 additional patents pending – All intellectual Property Rights are 100% Company Owned
USA
GRANTED
Patent Number
12,442,495
CANADA
GRANTED
Patent Number
2,665,816
EU
GRANTED
Patent Number
07827143.4
ISRAEL
GRANTED
Patent Number
197737
AUSTRALIA
GRANTED
Patent Number
2007298494
INDIA
PENDING
Patent Number
2595/DELNP/2009
ImMucin™ is the first immunotherapy to be derived from VaxHit platform, and has also been granted Orphan Drug Status from both the USA FDA and the EU EMA agencies, which provide certain additional incentives and market exclusivity.
USA
GRANTED
Patent Number
12,442,495
CANADA
GRANTED
Patent Number
2,665,816
EU
GRANTED
Patent Number
07827143.4
ISRAEL
GRANTED
Patent Number
197737
AUSTRALIA
GRANTED
Patent Number
2007298494
INDIA
PENDING
Patent Number
2595/DELNP/2009
Vaxil’s ImMucin™ immunotherapy was awarded Orphan Drug Status from the USA FDA and the European EMA agencies
ImMucin™ has completed a Phase I/II which included 15 myeloma cancer patients and validated VaxHit’s potential
as a platform for targeting renowned cancer antigens in an altogether unique and advantageous manner
Antibodies directed against signal peptides domains
USA
PENDING
Patent Number
14,344,837
CANADA
PENDING
Patent Number
2,848,819
ISRAEL
PENDING
Patent Number
231507
AUSTRALIA
PENDING
Patent Number
2012310086
INDIA
PENDING
Patent Number
2720/DELNP/2014
Antigen specific multiple epitope anti-infective
USA
GRANTED
Patent Number
13,384,286
EU
PENDING
Patent Number
10747083.3
INDIA
PENDING
Patent Number
1224/CHENP/2012
South Africa
GRANTED
Patent Number
2012/01137
Patent Family 1
Antigen Specific Multiple Epitope Vaccines
- Vaxil’s primary technology recently completed succesful Phase-I/II clinical trial in 15 MM patients
- ImMucin™ officially received “Orphan Drug Status” for MM from the EMA in March of 2015
- Patent pending in USA, Europe, Canada, India, and granted in Israel and Australia
Patent Family 2
Proprietary Recombinant Antibodies Including Companion Diagnostic for ImMucin
- “These findings suggest a novel cell surface presence of MUC1 SP domain, a potential therapeutic benefit for anti-MUC1 antibodies in MUC1-positive tumors and a selection tool for MM patients to be treated with the anti-MUC1 SP vaccine, ImMucin™”
- Patent pending in several countries
Patent Family 3
Antigen Specific Multiple Epitope Anti-Infectives
- Pre-Clinical Study included “21 patients, representing diverse ethnic groups, with a history of Tuberculosis”
- Vaxil intends to seek a partner for development of this area, maintaining focus on immuno-oncology
- Patents granted in South Africa and pending in USA, Europe, and India